Comparative Pharmacology
Head-to-head clinical analysis: CINOBAC versus NEGGRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOBAC versus NEGGRAM.
CINOBAC vs NEGGRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cinobufagin, a bufadienolide from toad venom, inhibits Na+/K+-ATPase, leading to increased intracellular calcium, and also induces apoptosis via caspase activation and modulation of signal transduction pathways including PI3K/Akt and MAPK.
Nalidixic acid is a quinolone antibacterial agent that inhibits bacterial DNA gyrase (topoisomerase II), thereby interfering with DNA replication and repair.
250 mg orally twice daily for 7-14 days
1 g orally four times daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; may be prolonged up to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
1-2 hours in normal renal function (terminal elimination half-life); prolonged to 6-12 hours in severe renal impairment (CrCl <20 mL/min)
Renal excretion of unchanged drug accounts for approximately 85-90% of elimination, with 10-15% metabolized hepatically to inactive glucuronide conjugates excreted in urine. Less than 2% is eliminated in feces via biliary excretion.
Renal: 85-90% (glomerular filtration and tubular secretion, 80% as unchanged drug, 5-10% as active metabolite 7-hydroxynalidixic acid); fecal: 4-5%
Category C
Category C
Quinolone Antibiotic
Quinolone Antibiotic